Oct 21, 2026 | News, Risk Management
On October 21, 2026, Franklin, Tennessee-based Lynch Regenerative Medicine, LLC (LRM) announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to proceed with a Phase 2 clinical trial evaluating...
Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
Aug 21, 2026 | News, Risk Management
Revance Therapeutics and Teoxane have officially announced FDA approval for RHA Redensity® Eye, expanding the Teoxane RHA® Collection into the delicate infraorbital region. The hyaluronic acid (HA) filler is specifically indicated for correcting moderate to severe...
Dec 12, 2025 | Legal Compliance, Risk Management
Introduction As more Nurse Practitioners (NPs) earn doctoral-level degrees, many understandably want to acknowledge their hard-earned credentials by using the title “Dr.” in clinical and professional settings. However, state laws, medical-board rules, and recent...
Oct 21, 2025 | Risk Management
In a move that has many in the longevity and wellness space buzzing, the FDA recently approved Elamipretide (SS-31) for the treatment of Barth syndrome, a rare mitochondrial disorder. While the approval targets a small patient population, the implications reach far...
Oct 20, 2025 | Risk Management
The U.S. Food and Drug Administration (FDA) recently released a safety communication highlighting serious risks associated with the use of radiofrequency (RF) microneedling devices. These systems, commonly marketed for skin tightening and rejuvenation, are now linked...
